Anglo-Swedish pharmaceutical giant AstraZeneca confessed in court documents that its COVID-19 vaccine, Covishield, might cause Thrombosis with Thrombocytopenia Syndrome (TTS), characterized by blood clots and lowered blood platelet count. This acknowledgment contradicts the company’s 2023 position, denying claims the vaccine was linked to TTS.
Developed with Oxford University, Covishield has been distributed in over 150 nations, notably the United Kingdom and India, where the Serum Institute of India produces it.
A class-action lawsuit before England’s High Court is seeking damages amounting to £100 million (~$125 million) for some 50 individuals who suffered severe injuries or death attributed to the vaccine.
AstraZeneca is fighting the lawsuit, but in newly disclosed February court filings, conceded that “[i]t is admitted that the AZ vaccine can, in very rare cases, cause TTS.”
They added that the “causal mechanism” for the condition is unknown and complained, “TTS can also occur in the absence of the AZ vaccine (or any vaccine).”
“The medical world has acknowledged for a long time that VITT was caused by the vaccine. It’s only AstraZeneca who have questioned whether Jamie’s condition was caused by the jab,” commented Kate Scott, wife of Jamie Scott, who was left with permanent brain damage after being vaccinated in April 2021.
VITT stands for vaccine-induced immune thrombocytopenia and thrombosis and was first identified by scientists in March 2021.
Studies of COVID-19 vaccines more generally have linked them to blood, brain, and heart conditions. Lieutenant Ted Macie, an active-duty Navy Medical Service Corps officer and whistleblower, claimed heart failure spiked by almost 1,000 percent among pilots in 2022 following the imposition of vaccine mandates on military personnel. Covid vaccines have also been linked to increased menstrual disturbances.